UroGen Pharma

UroGen is a biotechnology company dedicated to developing and commercializing innovative solutions for the treatment of urothelial cancer and specialty cancers. UroGen has developed RTGel® Reverse Thermal Gel, a proprietary hydrogel-based sustained-release platform technology with the potential to enhance the therapeutic benefits of existing drugs. UroGen's sustained-release technology is designed to enable longer drug exposure to urinary tract tissues, making localized treatment a potentially more effective option. JELMYTO® (mitomycin) for intravesical solution is used for low-grade non-muscle invasive bladder cancer, while UGN-102 (Mitomycin) is an investigational therapy aimed at ablating tumors through non-surgical means.